338 results on '"Morenghi E"'
Search Results
52. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma
- Author
-
Santoro, A., primary, Magagnoli, M., additional, Spina, M., additional, Pinotti, G., additional, Siracusano, L., additional, Michieli, M., additional, Nozza, A., additional, Sarina, B., additional, Morenghi, E., additional, Castagna, L., additional, Tirelli, U., additional, and Balzarotti, M., additional
- Published
- 2007
- Full Text
- View/download PDF
53. Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer
- Author
-
Miranda, E, primary, Destro, A, additional, Malesci, A, additional, Balladore, E, additional, Bianchi, P, additional, Baryshnikova, E, additional, Franchi, G, additional, Morenghi, E, additional, Laghi, L, additional, Gennari, L, additional, and Roncalli, M, additional
- Published
- 2006
- Full Text
- View/download PDF
54. Micrometastasis in sentinel (SLN) and non-sentinel lymph nodes of breast cancer: An update including clinico-pathologic impact and survival
- Author
-
Masci, G., primary, Di Tommaso, L., additional, Del Prato, I., additional, Orefice, S. E., additional, Gullo, G., additional, Rubino, A., additional, Eboli, M. W., additional, Morenghi, E., additional, Roncalli, M., additional, and Santoro, A., additional
- Published
- 2006
- Full Text
- View/download PDF
55. Critical evaluation of the role of oxaliplatin- and irinotecan-based regimens as first-line chemotherapy in advanced colorectal cancer (CRC)
- Author
-
Carnaghi, C., primary, Rimassa, L., additional, Zuradelli, M., additional, Morenghi, E., additional, Torri, V., additional, Tronconi, M. C., additional, Pressiani, T., additional, and Santoro, A., additional
- Published
- 2006
- Full Text
- View/download PDF
56. Clinical phenotype and β-cell autoimmunity in Italian patients with adult-onset diabetes
- Author
-
Genovese, S, primary, Bazzigaluppi, E, additional, Gonçalves, D, additional, Ciucci, A, additional, Cavallo, M G, additional, Purrello, F, additional, Anello, M, additional, Rotella, C M, additional, Bardini, G, additional, Vaccaro, O, additional, Riccardi, G, additional, Travaglini, P, additional, Morenghi, E, additional, Bosi, E, additional, and Pozzilli, P, additional
- Published
- 2006
- Full Text
- View/download PDF
57. Retrospective analysis of central venous catheter-related thrombosis in 427 cancer patients prophylaxed with low-dose warfarin
- Author
-
Magagnoli, M., primary, Masci, G., additional, Castagna, L., additional, Zucali, P. A., additional, Pedicini, V., additional, Bramanti, S., additional, Balzarotti, M., additional, Morenghi, E., additional, and Santoro, A., additional
- Published
- 2004
- Full Text
- View/download PDF
58. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer
- Author
-
Parra, H S, primary, Cavina, R, additional, Latteri, F, additional, Zucali, P A, additional, Campagnoli, E, additional, Morenghi, E, additional, Grimaldi, G C, additional, Roncalli, M, additional, and Santoro, A, additional
- Published
- 2004
- Full Text
- View/download PDF
59. Feasibility of combination of cisplatin (CDDP) and gemcitabine (GEM) in non-small cell lung cancer and other solid tumors: analysis of dose-intensity (DI) and compliance of four different schedules
- Author
-
Hector, S.P., primary, Cavina, R., additional, Sala, A., additional, Latteri, F., additional, Campagnoli, E., additional, Ginanni, V., additional, Morenghi, E., additional, Rimassa, L., additional, Biancofiore, G., additional, and Santoro, A., additional
- Published
- 2001
- Full Text
- View/download PDF
60. Superiority of three-week vs. four-week schedule of cisplatin (CDDP) and gemcitabine (GEM): Results of a randomized phase II study
- Author
-
Soto Parra, H.J, primary, Cavina, R, additional, Antonelli, G, additional, Latteri, F, additional, Sala, A, additional, Dambrosio, M, additional, Alloisio, M, additional, Morenghi, E, additional, Bufalino, R, additional, and Santoro, A, additional
- Published
- 2000
- Full Text
- View/download PDF
61. Surgical procedures in the DANTE trial, a randomized study of lung cancer early detection with spiral computed tomography: comparative analysis in the screening and control arm.
- Author
-
Infante M, Chiesa G, Solomon D, Morenghi E, Passera E, Lutman FR, Bottoni E, Cariboni U, Errico V, Voulaz E, Ferraroli G, Testori A, Inzirillo F, Chiarenza M, Roncalli M, Cavuto S, Chiti A, Alloisio M, Ravasi G, and DANTE Study Group
- Published
- 2011
- Full Text
- View/download PDF
62. Drug-eluting stents for the percutaneous treatment of the anastomosis of the left internal mammary graft to left anterior descending artery.
- Author
-
Zavalloni D, Rossi ML, Scatturin M, Morenghi E, Soregaroli D, Municino A, Gasparini GL, Lisignoli V, Barbaro C, and Presbitero P
- Published
- 2007
- Full Text
- View/download PDF
63. Clinical phenotype and {szligbeta}-cell autoimmunity in Italian patients with adult-onset diabetes
- Author
-
Genovese, S, Bazzigaluppi, E, Gonçalves, D, Ciucci, A, Cavallo, M G, Purrello, F, Anello, M, Rotella, C M, Bardini, G, Vaccaro, O, Riccardi, G, Travaglini, P, Morenghi, E, Bosi, E, and Pozzilli, P
- Abstract
OBJECTIVE: To characterize the phenotype of a large population of Italian patients with adult onset (≥40 years) diabetes who were attending outpatient clinics and who were screened for glutamic acid decarboxylase 65 autoantibodies (GADA), protein tyrosine phosphatase IA-2 (IA-2A) and IA-2{szligbeta}/phogrin (IA-2{szligbeta}A). Design and methods: This was a cross-sectional study comprising a total of 881 patients, aged ≤ 70 years, diagnosed with type 2 diabetes after the age of 40 years, and consecutively recruited in five clinics located in different geographic areas of Italy (Milan, Florence, Rome, Naples and Catania). Their mean disease duration was 8.1 (6.9; S.D.) years. GADA, IA-2A and IA-2{szligbeta}A were measured with radiobinding assays with in vitro translated S-methionine-labelled glutamic acid decarboxylase 65 (GAD65) or IA-2 or IA-2{szligbeta}. Anthropometric and clinical data were collected and compared amongst patients with or without autoantibodies. RESULTS: Sixty-three (7.1%) patients had one or more autoantibodies, 58 (6.6%) had GADA, 22 (2.5%) had IA-2A, six (0.7%) had IA-2{szligbeta}A and 19 (2.15%) had two or more autoantibodies. IA-2A or IA-2{szligbeta}A, in the absence of GADA, were found in only five patients. Autoantibody-positive patients were more often female (63.5 vs 36.5%; P < 0.009), had higher glycated haemoglobin (Hb A1c) (P < 0.001), lower body mass index (BMI; P < 0.0005) and waist/hip ratio (WHR; P < 0.01); female gender being the main contributor to BMI and WHR. We did not observe any differences in age at diagnosis or duration of disease with respect to the presence or absence of islet autoantibodies. The proportion of patients on insulin therapy was higher in patients with two or more antibodies, compared with those with one antibody only, and no antibodies (P for trend < 0.001), and among patients with GADA, in those with higher antibody titre (73.9% in those with > 10 units vs 42.0% in those with ≤ 10 units; P < 0.007). CONCLUSIONS: Patients with adult onset diabetes characterized by autoimmunity to {szligbeta}-cells showed a clinical phenotype with anthropometric features that differed from those classically observed in patients with type 2 diabetes. The number and titre of autoantibodies, which reflect the severity of autoimmunity and {szligbeta}-cell impairment, amplified this difference. The usefulness of autoantibody screening in adult-onset diabetes is further emphasized by these findings.
- Published
- 2006
64. RETROSPECTIVE ANALYSIS OF VYGON CATHETER IN 302 CANCER PATIENTS: SAFETY, EFFICACY AND COMPLICATIONS
- Author
-
Masci, G., Magagnoli, M., Castagna, L., Vincenzo, F., Carnaghi, C., Paolo Zucali, Pedicini, V., Bramanti, S., Morenghi, E., and Santoro, A.
65. ROLE OF 11C-METHIONINE PET/CT FOR RADIOTHERAPY PLANNING OF PATIENTS AFFECTED BY PRIMARY BRAIN TUMOUR
- Author
-
Lopci, E., Elena Clerici, Catalano, M., Rodari, M., Morenghi, E., Mancosu, P., Navarria, P., Scorsetti, M., and Chiti, A.
66. Activity of the epidermal growth factor receptor inhibitor gefitinib ('Iressa', ZD1839) in refractory non-small-cell lung cancer
- Author
-
Parra, Hs, Cavina, R., Paolo Zucali, Campagnoli, E., Latteri, F., Biancofiore, G., Abbadessa, G., Morenghi, E., and Santoro, A.
67. A. Micrometastasis in sentinel (SLN) and non sentinel lymph nodes of breast cancer: an update including clinico-pathologic impact and survaival
- Author
-
Masci, G., luca di tommaso, Del Prato, I., Orefice, S., Rubino, A., Morenghi, E., Salvini, P., Alloisio, M., Roncalli, M., and Armando Santoro
68. Gardnerella, Trichomonas vaginalis, Candida, Chlamydia trachomatis, Mycoplasma hominis and Ureaplasma urealyticum in the genital discharge of symptomatic fertile and asymptomatic infertile women
- Author
-
Casari, E., Ferrario, A., Morenghi, E., and Alessandro Montanelli
69. RETROPERITONEAL SARCOMA: RETROSPECTIVE ANALYSIS OF A LARGE SINGLE INSTITUTION SERIES
- Author
-
Coladonato, M., Mussi, C., Morenghi, E., Bagnoli, P., Pedrazzoli, P., Secondino, S., Armando Santoro, and Quagliuolo, V.
70. Poor outcome in patients treated with brachytherapy for diffuse in-stent restenosis. The role of additional stenting despite prolonged antiplatelet therapy
- Author
-
Zavalloni, D., Rossi, M., Belli, G., Scatturin, M., Morenghi, E., Marsico, F., Catalano, G., giovanni tosi, Pagnotta, P., and Presbitero, P.
71. Prophylaxis of central venous catheter-related thrombosis with minidose warfarin: Analysis of its use in 427 cancer patients
- Author
-
Magagnoli, M., giovanna masci, Castagna, L., Zucali, P. A., Morenghi, E., Pedicini, V., and Santoro, A.
72. FluCyD combination in low-grade lymphomas: An active regimen for selected patients
- Author
-
Siracusano, L., Balzarotti, M., Magagnoli, M., Castagna, L., Ripa, C., Nozza, A., Torri, W., Sarina, B., Isa, L., Alexia Francesca Bertuzzi, Timofeeva, I., Morenghi, E., and Santoro, A.
73. COMPARISON OF TWO-YEAR RESPONSE TO LENALIDOMIDE OR PERIPHERAL BLOOD STEM-CELL TRANSPLANTATION IN PATIENTS WITH POEMS
- Author
-
Bianco, M., Terenghi, F., Gallia, F., Nozza, A., Scarale, A., Fayoumi, M. Z., Claudia Giannotta, Morenghi, E., and Nobile-Orazio, E.
74. Gefitinib ('Iressa', ZD1839) in elderly patients with progressive pretreated non-small-cell lung cancer: results from the Istituto Clinico Humanitas
- Author
-
Parra, Hs, Cavina, R., Paolo Zucali, Campagnoli, E., Latteri, F., Biancofiore, G., Abbadessa, G., Morenghi, E., and Santoro, A.
75. Surgery followed by radiotherapy for the treatment of metastatic epidural spinal cord compression from breast cancer.
- Author
-
Tancioni F, Navarria P, Mancosu P, Pedrazzoli P, Morenghi E, Santoro A, Baena RR, and Scorsetti M
- Published
- 2011
- Full Text
- View/download PDF
76. Superiority of three-week vs. four-week schedule of cisplatin (CDDP) and gemcitabine (GEM): Results of a randomized phase II study
- Author
-
Parra, H. J. Soto, Cavina, R., Antonelli, G., Latteri, F., Sala, A., Dambrosio, M., Alloisio, M., Morenghi, E., Bufalino, R., and Santoro, A.
- Published
- 2000
- Full Text
- View/download PDF
77. Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy
- Author
-
Girolama Alessandra Marfia, Giovanni Antonini, Giuseppe Cosentino, Tiziana Rosso, Giuseppe Lauria, Fiore Manganelli, Francesca Gallia, Angelo Maurizio Clerici, Dario Cocito, Pietro Emiliano Doneddu, Guido Cavaletti, Massimiliano Filosto, F. Terenghi, Eduardo Nobile-Orazio, Claudia Giannotta, Emanuela Morenghi, Blesson Punnen Sajeev, Giuseppe Liberatore, Liberatore, G., Giannotta, C., Sajeev, B. P., Morenghi, E., Terenghi, F., Gallia, F., Doneddu, P. E., Manganelli, F., Cocito, D., Filosto, M., Antonini, G., Cosentino, G., Marfia, G. A., Clerici, A. M., Lauria, G., Rosso, T., Cavaletti, G., Nobile-Orazio, E., Liberatore, G, Giannotta, C, Sajeev, B, Morenghi, E, Terenghi, F, Gallia, F, Doneddu, P, Manganelli, F, Cocito, D, Filosto, M, Antonini, G, Cosentino, G, Marfia, G, Clerici, A, Lauria, G, Rosso, T, Cavaletti, G, and Nobile-Orazio, E
- Subjects
0301 basic medicine ,medicine.medical_specialty ,anti-MAG polyneuropathy ,chronic inflammatory demyelinating polyradiculoneuropathy ,ELISA ,sensitivity ,specificity ,autoantibodies ,case-control studies ,enzyme-linked immunosorbent assay ,humans ,myelin-associated glycoprotein ,polyneuropathies ,retrospective studies ,Immunology ,Anti-MAG polyneuropathy ,Enzyme-Linked Immunosorbent Assay ,Settore MED/26 ,Gastroenterology ,Polyneuropathies ,03 medical and health sciences ,Sensitivity ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Immunology and Allergy ,In patient ,Autoantibodies ,Retrospective Studies ,Anti-MAG polyneuropathy, chronic inflammatory demyelinating polyradiculoneuropathy ,biology ,business.industry ,Anti mag ,Specificity ,medicine.disease ,Autoantibodie ,Myelin-Associated Glycoprotein ,Titer ,030104 developmental biology ,Polyneuropathie ,nervous system ,Neurology ,Case-Control Studies ,Elisa test ,biology.protein ,Neurology (clinical) ,Antibody ,Case-Control Studie ,business ,Sensitivity (electronics) ,Polyneuropathy ,030217 neurology & neurosurgery ,Human - Abstract
For the diagnosis of anti-MAG polyneuropathy the commercial ELISA manufacturer currently recommends a cut-off of 1000 Bühlmann Titer Units (BTU). We analyzed sera from 80 anti-MAG neuropathy patients and 383 controls (with other neuropathies or healthy controls) to assess the ELISA sensitivity and specificity at different thresholds. A better combination of sensitivity/specificity was found at a threshold >1500 BTU than at >1000 BTU. The best value of specificity was obtained at threshold >7000 BTU. There was a diagnostic grey area between 1500 and 7000 BTU in which the clinical phenotypes as well as electrophysiological studies need to be carefully assessed particularly to differentiate CIDP and anti-MAG neuropathy.
- Published
- 2020
78. Dipeptidyl Peptidase 3 Activity as a Promising Biomarker of Bone Fragility in Postmenopausal Women
- Author
-
Ciro Menale, Gaia Tabacco, Anda Mihaela Naciu, Maria Lucia Schiavone, Francesca Cannata, Emanuela Morenghi, Cristina Sobacchi, Andrea Palermo, Menale, C., Tabacco, G., Naciu, A. M., Schiavone, M. L., Cannata, F., Morenghi, E., Sobacchi, C., and Palermo, A.
- Subjects
NF-E2-Related Factor 2 ,Dpp3 ,oxidative stress ,bone mineral density ,osteoporosis ,fragility fracture ,serum biomarker ,Pharmaceutical Science ,Analytical Chemistry ,Mice ,Bone Density ,Drug Discovery ,Animals ,Humans ,osteoporosi ,Prospective Studies ,Physical and Theoretical Chemistry ,Dipeptidyl-Peptidases and Tripeptidyl-Peptidases ,Osteoporosis, Postmenopausal ,oxidative stre ,Kelch-Like ECH-Associated Protein 1 ,Bone Density Conservation Agents ,Organic Chemistry ,Postmenopause ,Cross-Sectional Studies ,Chemistry (miscellaneous) ,Molecular Medicine ,Osteoporosis ,Female ,Denosumab ,Biomarkers - Abstract
The dipeptidyl peptidase 3 (Dpp3) is a ubiquitous zinc-dependent aminopeptidase, participating in the activation or degradation of signaling peptides and in the Keap1–Nrf2 antioxidant pathway. The absence of Dpp3 in the Dpp3 knockout mouse model causes increased osteoclast activity, altered osteogenic function, sustained oxidative stress in the bone tissue, and bone loss. We aimed to assess the association of Dpp3 activity with bone fragility in postmenopausal osteoporosis and the impact of denosumab on enzymatic activity. We conducted a two-phase study including 69 postmenopausal women with severe osteoporosis and 36 postmenopausal women without osteometabolic conditions, as controls (cross-sectional phase). Subjects with severe osteoporosis were assessed at baseline and 14 days after the first denosumab administration (prospective phase). The results showed significant reduction in serum Dpp3 activity (expressed as nmoles of formed product/mg proteins/min) in patients vs. controls (0.791 ± 0.232 vs. 1.195 ± 0.338; p < 0.001), and significant association with bone mass at the femoral neck (r = 0.28, p = 0.02) in patients prior to treatment. We found a negative correlation between C-terminal telopeptide (CTX) or N-terminal pro-peptide of type 1 procollagen (P1NP) levels and Dpp3 activity (respectively, r = −0.29, p = 0.012; and r = −0.2572, p = 0.033). Dpp3 activity did not change after denosumab injection. Our findings support a critical role played by Dpp3 in bone homeostasis as a potential bone protective factor. Additional clinical studies in larger cohorts might explore the implementation of Dpp3 assessment as a biomarker of bone health status.
- Published
- 2022
79. OCT changes of idiopathic epiretinal membrane after cataract surgery
- Author
-
Paolo Vinciguerra, Mary Romano, Alfredo Borgia, Luca Pagano, Emanuela Morenghi, Jose Luis Vallejo-Garcia, Alessio Montericcio, Vallejo-Garcia, J. L., Romano, M., Pagano, L., Montericcio, A., Borgia, A., Morenghi, E., and Vinciguerra, P.
- Subjects
medicine.medical_specialty ,genetic structures ,medicine.medical_treatment ,Glaucoma ,Vitrectomy ,Cataract surgery ,Retina ,03 medical and health sciences ,0302 clinical medicine ,Epiretinal membrane ,lcsh:Ophthalmology ,medicine ,030212 general & internal medicine ,Macular edema ,Peeling ,business.industry ,Retinal detachment ,Diabetic retinopathy ,Macular degeneration ,medicine.disease ,eye diseases ,Surgery ,Ophthalmology ,lcsh:RE1-994 ,030221 ophthalmology & optometry ,Original Article ,sense organs ,business - Abstract
Background We reviewed our experience in the management of cataract and idiopatic epiretinal membrane surgeries at the Humanitas Research Institute–Milan, Italy- over the past 3 years. Methods We conducted a single center retrospective observational case series of patients that underwent sequential cataract and idiopatic epiretinal membrane (ERM) surgeries from 2012–2015 in Humanitas Research Institute. Full data was obtained for 53 eyes of 57 patients. Patients with ERM secondary to uveitis or trauma or associated with simultaneous retinal detachment were excluded. Diabetic retinopathy, glaucoma, age-related macular degeneration, and myopia of more than 6 diopters were exclusion criteria as well. Results Cataract surgery was not associated with an ERM stage progression at one month follow up, but caused retinal inflammation that resulted in a significant increase in central macular thickness (CMT), macular volume (MV), central macular edema (CME), IS/OS disruption (IS/OS) and neurosensory detachment (NSD). However, there was no significant change in Best corrected visual acuity (BCVA). Conclusion We suggest that patients undergoing cataract surgery in the presence of epiretinal membranes need tight follow up to treat and control eventual macular inflammatory changes and eventual prompt vitrectomy if BCVA is threatened.
- Published
- 2020
80. Treatment of acromegalic osteopathy in real-life clinical practice: The BAAC (bone active drugs in acromegaly) study
- Author
-
Carolina Di Somma, Silvia Grottoli, Andrea Lania, Emanuele Ferrante, Filippo Maffezzoni, Miriam Cellini, Iacopo Chiodini, Maura Arosio, Emanuela Morenghi, Laura De Marinis, Teresa Porcelli, Flavia Pugliese, Alberto Ferlin, Roberto Olivetti, Giulia Del Sindaco, Elisabetta Lavezzi, Alfredo Scillitani, Ludovica F S Grasso, Sabrina Chiloiro, Massimo Procopio, Antonio Bianchi, Rosario Pivonello, Marco Barale, Antonella Giampietro, Giovanna Mantovani, Federico Gatto, Nunzia Prencipe, Gherardo Mazziotti, Claudia Battista, Ezio Ghigo, Mazziotti, G., Battista, C., Maffezzoni, F., Chiloiro, S., Ferrante, E., Prencipe, N., Grasso, L., Gatto, F., Olivetti, R., Arosio, M., Barale, M., Bianchi, A., Cellini, M., Chiodini, I., de Marinis, L., Sindaco, G. D., Somma, C. D., Ferlin, A., Ghigo, E., Giampietro, A., Grottoli, S., Lavezzi, E., Mantovani, G., Morenghi, E., Pivonello, R., Porcelli, T., Procopio, M., Pugliese, F., Scillitani, A., and Lania, A. G.
- Subjects
Male ,Endocrinology, Diabetes and Metabolism ,Clinical Biochemistry ,Osteoporosis ,Biochemistry ,0302 clinical medicine ,Endocrinology ,Bone Density ,Teriparatide ,Longitudinal Studies ,Practice Patterns, Physicians' ,Bone Density Conservation Agents ,Bisphosphonates ,Middle Aged ,Denosumab ,Italy ,030220 oncology & carcinogenesis ,Vertebral fractures ,Spinal Fractures ,Female ,Bone Diseases ,medicine.drug ,Adult ,medicine.medical_specialty ,030209 endocrinology & metabolism ,Acromegaly ,Bone-active drugs ,Lower risk ,03 medical and health sciences ,Internal medicine ,Hypoadrenalism ,medicine ,Humans ,Bisphosphonate ,Aged ,Retrospective Studies ,business.industry ,Biochemistry (medical) ,Osteoporosi ,Settore MED/13 - ENDOCRINOLOGIA ,Odds ratio ,medicine.disease ,Osteopathy ,Bone-active drug ,business ,Complication - Abstract
Background Vertebral fractures (VFs) are a frequent complication of acromegaly, but no studies have been so far published on effectiveness of antiosteoporotic drugs in this clinical setting. Objective To evaluate whether in real-life clinical practice bone active drugs may reduce the risk of VFs in patients with active or controlled acromegaly. Study design Retrospective, longitudinal study including 9 tertiary care endocrine units. Patients and Methods Two hundred and forty-eight patients with acromegaly (104 males; mean age 56.00 ± 13.60 years) were evaluated for prevalent and incident VFs by quantitative morphometric approach. Bone active agents were used in 52 patients (20.97%) and the median period of follow-up was 48 months (range 12-132). Results During the follow-up, 65 patients (26.21%) developed incident VFs in relationship with pre-existing VFs (odds ratio [OR] 3.75; P Conclusions Bone active drugs may prevent VFs in patients with active acromegaly.
- Published
- 2020
81. Robotic resection of Stage III lung cancer: an international retrospective study†
- Author
-
Robert J. Cerfolio, Waël C. Hanna, Jacques P. Fontaine, Bernard J. Park, Emanuela Morenghi, Marco Alloisio, Pierluigi Novellis, Alpert Toker, Frank O. Velez-Cubian, Eric M. Toloza, Mark R. Dylewski, Giulia Veronesi, Marisa Amaral, Elisa Dieci, Veronesi, G, Park, B, Cerfolio, R, Dylewski, M, Toker, A, Fontaine, Jp, Hanna, Wc, Morenghi, E, Novellis, P, Velez-Cubian, Fo, Amaral, Mh, Dieci, E, Alloisio, M, Toloza, Em, Casiraghi, Monica, and Spaggiari, Lorenzo
- Subjects
Male ,Lung Neoplasms ,Thoracic ,medicine.medical_treatment ,Kaplan-Meier Estimate ,030204 cardiovascular system & hematology ,Postoperative Complications ,0302 clinical medicine ,Robotic Surgical Procedures ,Interquartile range ,Carcinoma, Non-Small-Cell Lung ,Carcinoid tumour ,Thoracotomy ,Pneumonectomy ,Neoadjuvant therapy ,Aged, 80 and over ,General Medicine ,Middle Aged ,Combined Modality Therapy ,Treatment Outcome ,Editorial ,medicine.anatomical_structure ,Surgical Manipulation ,Cardiothoracic surgery ,Lymphatic Metastasis ,030220 oncology & carcinogenesis ,Female ,Cardiology and Cardiovascular Medicine ,Pulmonary and Respiratory Medicine ,Stage III Lung Cancer ,medicine.medical_specialty ,Postoperative pain ,Resection ,03 medical and health sciences ,medicine ,Humans ,Minimally Invasive Surgical Procedures ,Lung cancer ,Aged ,Neoplasm Staging ,Retrospective Studies ,Lung ,business.industry ,Induction chemotherapy ,Retrospective cohort study ,Perioperative ,medicine.disease ,Surgery ,030228 respiratory system ,Invasive surgery ,Neoplasm Recurrence, Local ,business - Abstract
Objectives Minimally invasive surgery is accepted for early-stage lung cancer, but its role in locally advanced disease is controversial, especially using a robotic platform. The aim of this retrospective study was to assess the safety and effectiveness of robot-assisted resection in patients with Stage IIIA non-small-cell lung cancer (NSCLC) or carcinoid tumours in the series as a whole and in different subgroups according to adjuvant treatment. Methods This was a retrospective multicentre study of consecutive patients with clinically evident or occult N2 disease (210 NSCLC and 13 carcinoid) who, in 2007-2016, underwent robot-assisted resection at 7 high-volume centres. Perioperative outcomes, recurrences and overall survival were assessed. Results N2 disease was diagnosed preoperatively in 72 (32%) patients and intraoperatively in 151 (68%) patients. Surgical margins were negative in 98.4% of cases with available data. Thirty-four (15.2%) patients received neoadjuvant treatment, 140 (63%) patients received postoperative treatment, and 49 (22%) patients underwent surgery only. There were 22 (9.9%) conversions to thoracotomy, 23 (10.3%) had serious (Grades III-IV) postoperative morbidity and the mean hospital stay was 5.3 days. Complications and outcomes did not differ significantly between treatment groups. Of the 34 patients who were given neoadjuvant chemotherapy, all had R0 resection, 5 (15%) patients required conversion but none required conversion because of bleeding and 4 (12%) patients had Grade III or IV postoperative complications. After a median of 18 (interquartile range 8-33) months, 3-year overall survival in NSCLC patients was 61.2% and 60.3% (P = 0.6) of patients in the subgroup were given induction treatment. However, overall survival was significantly better (P = 0.012) in NSCLC patients with ≤2 positive nodes (vs >2). Nineteen (8.5%) patients developed local recurrence. Conclusions Robot-assisted lobectomy is safe and effective in patients with Stage III NSCLC or carcinoid tumours with low conversions and complications. Among patients with NSCLC, including those who were given induction chemotherapy, survival was similar to that reported for open surgery.
- Published
- 2018
82. Radical thymectomy versus conservative thymomectomy in the surgical treatment of thymic malignancies
- Author
-
Umberto Cariboni, Emanuele Voulaz, Marco Alloisio, Giulia Veronesi, Eliseo Passera, Maurizio Infante, Edoardo Bottoni, Alberto Testori, Emanuela Morenghi, Pierluigi Novellis, Voulaz, E, Veronesi, G, Infante, M, Cariboni, U, Testori, A, Novellis, P, Bottoni, E, Passera, E, Morenghi, E, and Alloisio, M
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Thymoma ,business.industry ,Proportional hazards model ,medicine.medical_treatment ,medicine.disease ,Malignancy ,Myasthenia gravis ,Surgery ,Thymectomy ,Medicine ,Original Article ,business ,Who classification ,Surgical treatment ,Thymic carcinoma - Abstract
Background: Complete thymectomy is recommended for thymic malignancies to reduce local recurrence and the likelihood of the long-term development of myasthenia gravis (MG). Thymus-conserving surgery (thymomectomy) seems to yield similar results, but evidence is still limited. The objective of this study was to assess if the oncological outcome, in terms of overall survival (OS) and disease-free survival (DFS), are comparable between radical thymectomy vs. conservative thymomectomy patients, and to assess if the outcome of the video-assisted thoracoscopic surgery (VATS) approach was similar to open surgery approach. Methods: We retrospectively analyzed 157 consecutive patients with either resectable thymoma or thymic carcinoma from two Italian centers (Humanitas Research Hospital, Milan, and Humanitas Gavazzeni, Bergamo) between 1997 and 2013 who underwent thymomectomy or extended thymectomy with the VATS or open approach; the patients with Miastenia Gravis underwent radical thymectomy. The patients were followed through physical examinations and phone interviews. Results: Thymomectomy and thymectomy were performed on 86 (54.8%) and 71 (45.2%) patients, respectively. Prognostic factors and comorbidities were comparable in the two groups. The median follow-up was 77 months. Cox proportional hazards model revealed that Masaoka advanced stage and thymic carcinoma of WHO classification were independent predictive factors for overall survival, but that the extent of surgery and the approach used (minimally invasive versus open) were not. Notably, five- and ten-year survival rates were similar in the two groups. Conclusions: In our experience, radical thymectomy and conservative thymomectomy did not differ in terms of disease-free and overall survival rates. In nonmyasthenic patients with early-stage resectable thymic malignancy, minimally invasive thymomectomy provided equivalent results to open thymectomy. Our results should be interpreted with caution due to the retrospective nature of the study. Well-designed, adequately-powered studies should be very welcome to increase the quantity and the quality of clinical evidence before incorporating this procedure in future guidelines.
- Published
- 2018
83. Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis
- Author
-
Emanuela Morenghi, Ana Lleo, Pietro Invernizzi, Peter Uhd Jepsen, Ian R. Mackay, Marco Carbone, Pier Maria Battezzati, Luca Moroni, Mauro Podda, M. Eric Gershwin, Lleo, A, Jepsen, P, Morenghi, E, Carbone, M, Moroni, L, Battezzati, P, Podda, M, Mackay, I, Gershwin, M, and Invernizzi, P
- Subjects
Male ,0301 basic medicine ,medicine.medical_specialty ,Pediatrics ,Denmark ,Population ,prevalence ,Prevalence ,Article ,03 medical and health sciences ,0302 clinical medicine ,Epidemiology ,cell immune-response ,medicine ,follow-up ,Journal Article ,Humans ,Registries ,education ,Survival analysis ,changing nomenclature ,Sex Characteristics ,education.field_of_study ,Multidisciplinary ,Liver Cirrhosis, Biliary ,Proportional hazards model ,business.industry ,Incidence ,Incidence (epidemiology) ,natural-history ,Survival Analysis ,pbc ,digestive system diseases ,ursodeoxycholic acid ,030104 developmental biology ,Italy ,primary sclerosing cholangiti ,Regression Analysis ,Female ,030211 gastroenterology & hepatology ,epidemiology ,business ,Sex ratio ,Demography ,Sex characteristics ,cirrhosi - Abstract
Primary biliary cholangitis (PBC) has been regarded as female-predominant without evidence of gender difference in survival. We aimed to compare the overall survival, incidence and prevalence of PBC in two well defined population-based studies over a recent decade, considering also sex ratios and mortality. We have taken advantage of population-wide records, during 2000–2009, in Lombardia, Northern Italy and Denmark. We focused on the incident cases of PBC, including gender and outcome, among 9.7 million inhabitants of Lombardia and 5.5 million of Denmark. In Lombardia there were 2,970 PBC cases with a female:male ratio of 2.3:1. The age/sex-adjusted annual incidence of PBC was 16.7 per million. Point prevalence was 160 per million on January 1st 2009. In Denmark there were 722 cases of incident PBC, female:male ratio was 4.2:1 and the annual incidence was 11.4 per million, a point prevalence of 115 per million in 2009. Cox regression multivariate analysis identified male sex as an independent predictor of all-cause mortality in both Italian (HR 2.36) and Danish population (HR 3.04). Our data indicate for PBC a sex ratio significantly lower than previously cited, a reversal of the usual latitudinal difference in prevalence and a surprisingly higher overall mortality for male patients.
- Published
- 2016
84. Surgical management of duodenal stump fistula after elective gastrectomy for malignancy: an Italian retrospective multicenter study
- Author
-
Alberto Marchet, Riccardo Rosati, Luca Gianotti, Luca Cozzaglio, Marco Giovenzana, Paolo Morgagni, Emanuela Morenghi, Vincenzo Mazzaferro, Lorenzo Cobianchi, Massimo Framarini, Leonardo Gerard, F. Roviello, Fausto Rosa, Vittorio Quagliuolo, Stefano Rausei, Fabrizio Romano, Roberto Biffi, Elena Orsenigo, Matteo Sacchi, Arianna Coniglio, Cozzaglio, L, Giovenzana, M, Biffi, R, Cobianchi, L, Coniglio, A, Framarini, M, Gerard, L, Gianotti, L, Marchet, A, Mazzaferro, V, Morgagni, P, Orsenigo, E, Rausei, S, Romano, F, Rosa, F, Rosati, R, Roviello, F, Sacchi, M, Morenghi, E, Quagliuolo, V, and Vittorio, Quagliuolo
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Complications ,Settore MED/18 - CHIRURGIA GENERALE ,medicine.medical_treatment ,Duodenal stump fistula ,Malignancy ,03 medical and health sciences ,0302 clinical medicine ,Postoperative Complications ,Surgical oncology ,Interquartile range ,Gastrectomy ,Stomach Neoplasms ,medicine ,MED/18 - CHIRURGIA GENERALE ,Intestinal Fistula ,Humans ,Duodenal Diseases ,Aged ,Retrospective Studies ,Surgery ,Laparotomy ,Vascular disease ,business.industry ,General surgery ,Mortality rate ,Gastroenterology ,General Medicine ,Odds ratio ,Middle Aged ,medicine.disease ,Prognosis ,Gastrectomy Complications Duodenal stump fistula Surgery ,Treatment Outcome ,Oncology ,Italy ,Elective Surgical Procedures ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Female ,Laparoscopy ,business ,Complication ,Abdominal surgery - Abstract
Background: Duodenal stump fistula (DSF) is a severe complication of gastrectomy. Although nonsurgical therapy is preferred, surgery is still mandatory in one third of DSF patients. The aim of this article is to analyze the surgical management of DSF and factors related to its outcome. Methods: We performed a retrospective multicenter study using data from January 1990 to November 2011 in 16 Italian surgery centers. We collected 8,268 elective gastrectomies for malignancies, 7,987 by the laparotomic and 281 by the laparoscopic approach. Two hundred five patients developed a DSF, 75 of whom underwent surgery for DSF. We analyzed mortality and DSF healing time as well as the impact of clinical, oncological, and surgical characteristics. Results: The laparoscopic approach increased the risk of DSF development (odds ratio 5.6, 95% confidence interval 2.7–10.6, P 
- Published
- 2014
85. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis
- Author
-
Raffaella Vecchione, M. A. Tommasini, Annarita Destro, Luigi Tornillo, Young Nyun Park, Luca Di Tommaso, Marco Montorsi, Emanuela Morenghi, Luigi Terracciano, Giada Franchi, Massimo Roncalli, Barbara Fiamengo, Guido Torzilli, DI TOMMASO, L, Franchi, G, Park, Yn, Fiamengo, B, Destro, A, Morenghi, E, Montorsi, M, Torzilli, G, Tommasini, M, Terracciano, L, Tornillo, L, Vecchione, Raffaela, and Roncalli, M.
- Subjects
Adult ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Pathology ,Cirrhosis ,Malignancy ,Glypican 3 ,Gastroenterology ,Sensitivity and Specificity ,Diagnosis, Differential ,Glypicans ,Glutamate-Ammonia Ligase ,Internal medicine ,Glutamine synthetase ,medicine ,Humans ,HSP70 Heat-Shock Proteins ,Aged ,Hepatology ,business.industry ,Nodule (medicine) ,Middle Aged ,medicine.disease ,Glutamine ,Hepatocytes ,Female ,medicine.symptom ,Differential diagnosis ,business ,Biomarkers - Abstract
Hepatocellular nodules in cirrhosis include regenerative (large regenerative, LRN) and dysplastic (low and high grade, LGDN and HGDN) nodules, early and grade 1 HCC (eHCC-G1), and overt HCC. The differential diagnosis may be particularly difficult when lesions such as HGDN and eHCC-G1 are involved. We investigated the diagnostic yield of a panel of 3 putative markers of hepatocellular malignancy such as HSP70, glypican 3 (GPC3), and glutamine synthetase (GS). We selected 52 surgically removed nonmalignant nodules (15 LRNs, 15 LGDNs, 22 HGDNs) and 53 HCCs (10 early, 22 grade 1, and 21 grade 2-3) and immunostained them for HSP70, GPC3, and GS. The sensitivity and specificity of the individual markers for the detection of eHCC-G1 were 59% and 86% for GS, 69% and 91% for GPC3, and 78% and 95% for HSP70. We identified 2 main phenotypes: (1) all negative, seen in 100% LRN and LGDN, 73% HGDN and 3% eHCC-G1; (2) all positive, a feature detected in less than half the eHCC-G1. Using a 3-marker panel, when at least 2 of them, regardless which, were positive, the sensitivity and specificity for the detection of eHCC-G1 were respectively 72% and 100%; the most sensitive combination was HSP70+/GPC3+ (59%) when a 2-marker panel was used. Conclusion: The adopted panel of 3 markers is very helpful in distinguishing eHCC-G1 from dysplastic nodules arising in cirrhosis. (HEPATOLOGY 2007;45:725–734.)
- Published
- 2007
86. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma
- Author
-
Maurizio Marangolo, Alessandra Bearz, P. Bidoli, Giovanni Luca Ceresoli, Emanuela Morenghi, Adolfo Favaretto, Hector Soto Parra, Armando Santoro, Guido Del Conte, Anna Ceribelli, Francesco Grossi, Paolo Andrea Zucali, Raffaele Cavina, Ceresoli, G, Zucali, P, Favaretto, A, Grossi, F, Bidoli, P, Del Conte, G, Ceribelli, A, Bearz, A, Morenghi, E, Cavina, R, Marangolo, M, Parra, H, and Santoro, A
- Subjects
Male ,Mesothelioma ,Cancer Research ,medicine.medical_specialty ,Guanine ,Neutropenia ,Pleural Neoplasms ,Phases of clinical research ,Pemetrexed ,Gastroenterology ,Carboplatin ,chemistry.chemical_compound ,Pleural disease ,Glutamates ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Aged ,business.industry ,Respiratory disease ,Anemia ,Middle Aged ,medicine.disease ,Surgery ,Clinical trial ,Treatment Outcome ,Oncology ,chemistry ,Expanded access ,Antifolate ,Female ,business ,medicine.drug - Abstract
PurposeThis multicenter, phase II clinical study was conducted to evaluate the activity of the combination of pemetrexed and carboplatin in patients with malignant pleural mesothelioma (MPM).Patients and MethodsChemotherapy-naive patients with measurable disease and adequate organ function, who were not eligible for curative surgery, received pemetrexed 500 mg/m2and carboplatin area under the plasma concentration-time curve of 5 mg/mL/min, administered intravenously every 21 days. All patients received folic acid and vitamin B12supplementation. Pemetrexed was provided within the Expanded Access Program.ResultsA total of 102 patients were enrolled. An objective response was achieved in 19 patients (two complete and 17 partial responses), for a response rate of 18.6% (95% CI, 11.6% to 27.5%). Forty-eight patients (47.0%; 95% CI, 37.1% to 57.2%) had stable disease after treatment. Overall, 67 patients (65.7%) achieved disease control (95% CI, 55.6% to 74.8%). Median time to progression was 6.5 months; median overall survival time was 12.7 months. Compliance to treatment was excellent, with a relative dose-intensity of 97% for pemetrexed and 98% for carboplatin. Toxicity was mild, with grade 3 or 4 neutropenia occurring in 9.7% of total cycles and grade 3 or 4 anemia occurring in 3.5% of total cycles. Nonhematologic toxicity was negligible.ConclusionTreatment with pemetrexed and carboplatin was active and well tolerated in patients with MPM. Disease control rate, time to disease progression, and overall survival were similar to the results achieved with the standard regimen of pemetrexed and cisplatin, suggesting that the carboplatin combination could be an alternative option for these patients.
- Published
- 2006
87. Clinical phenotype and beta-cell autoimmunity in Italian patients with adult-onset diabetes
- Author
-
Paolo Pozzilli, Carlo Maria Rotella, Gabriele Riccardi, G. Bardini, P. Travaglini, A. Ciucci, D. Gonca̧lves, Francesco Purrello, Elena Bazzigaluppi, Maria Gisella Cavallo, O. Vaccaro, Emanuela Morenghi, M. Anello, Emanuele Bosi, Stefano Genovese, Genovese, Salvatore, Bazzigaluppi, E, Goncalves, D, Ciucci, A, Cavallo, Mg, Purrello, F, Anello, M, Rotella, Cm, Bardini, G, Vaccaro, Olga, Riccardi, Gabriele, Travaglini, P, Morenghi, E, Bosi, E, Pozzilli, P., Genovese, S, Vaccaro, O, Riccardi, G, and Bosi, Emanuele
- Subjects
Male ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Glutamate decarboxylase ,Disease ,Type 2 diabetes ,medicine.disease_cause ,Autoimmunity ,Body Mass Index ,Endocrinology ,adult-onset diabetes ,Internal medicine ,Diabetes mellitus ,Insulin-Secreting Cells ,medicine ,Outpatient clinic ,Humans ,beta-cell autoimmunity ,Aged ,Autoantibodies ,Glycated Hemoglobin ,business.industry ,Glutamate Decarboxylase ,Waist-Hip Ratio ,Autoantibody ,General Medicine ,Middle Aged ,medicine.disease ,Cross-Sectional Studies ,Phenotype ,Diabetes Mellitus, Type 2 ,Italy ,Female ,Age of onset ,Protein Tyrosine Phosphatases ,business - Abstract
Objective: To characterize the phenotype of a large population of Italian patients with adult onset (≥40 years) diabetes who were attending outpatient clinics and who were screened for glutamic acid decarboxylase 65 autoantibodies (GADA), protein tyrosine phosphatase IA-2 (IA-2A) and IA-2β/phogrin (IA-2βA).Design and methods: This was a cross-sectional study comprising a total of 881 patients, aged ≤ 70 years, diagnosed with type 2 diabetes after the age of 40 years, and consecutively recruited in five clinics located in different geographic areas of Italy (Milan, Florence, Rome, Naples and Catania). Their mean disease duration was 8.1 (6.9;s.d.) years. GADA, IA-2A and IA-2βA were measured with radiobinding assays within vitrotranslated S-methionine-labelled glutamic acid decarboxylase 65 (GAD65) or IA-2 or IA-2β. Anthropometric and clinical data were collected and compared amongst patients with or without autoantibodies.Results: Sixty-three (7.1%) patients had one or more autoantibodies, 58 (6.6%) had GADA, 22 (2.5%) had IA-2A, six (0.7%) had IA-2βA and 19 (2.15%) had two or more autoantibodies. IA-2A or IA-2βA, in the absence of GADA, were found in only five patients. Autoantibody-positive patients were more often female (63.5 vs 36.5%;P< 0.009), had higher glycated haemoglobin (Hb A1c) (P< 0.001), lower body mass index (BMI;P< 0.0005) and waist/hip ratio (WHR;P< 0.01); female gender being the main contributor to BMI and WHR. We did not observe any differences in age at diagnosis or duration of disease with respect to the presence or absence of islet autoantibodies. The proportion of patients on insulin therapy was higher in patients with two or more antibodies, compared with those with one antibody only, and no antibodies (Pfor trend < 0.001), and among patients with GADA, in those with higher antibody titre (73.9% in those with > 10 units vs 42.0% in those with ≤ 10 units;P< 0.007).Conclusions: Patients with adult onset diabetes characterized by autoimmunity to β-cells showed a clinical phenotype with anthropometric features that differed from those classically observed in patients with type 2 diabetes. The number and titre of autoantibodies, which reflect the severity of autoimmunity and β-cell impairment, amplified this difference. The usefulness of autoantibody screening in adult-onset diabetes is further emphasized by these findings.
- Published
- 2006
88. DXA-derived lumbar bone strain index corrected for kyphosis is associated with vertebral fractures and trabecular bone score in acromegaly.
- Author
-
Jaafar S, Cristofolini G, Morenghi E, Rinaudo L, Birtolo MF, Sala E, Ferrante E, Mungari R, Lavezzi E, Leonardi L, Ragucci P, Ulivieri FM, Balzarini L, Mantovani G, Lania AG, and Mazziotti G
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Adult, Acromegaly complications, Acromegaly physiopathology, Acromegaly diagnostic imaging, Spinal Fractures diagnostic imaging, Spinal Fractures etiology, Lumbar Vertebrae diagnostic imaging, Absorptiometry, Photon, Cancellous Bone diagnostic imaging, Kyphosis diagnostic imaging, Bone Density
- Abstract
Purpose: The bone strain index (BSI) is a marker of bone deformation based on a finite element analysis inferred from dual X-ray absorptiometry (DXA) scans, that has been proposed as a predictor of fractures in osteoporosis (i.e., higher BSI indicates a lower bone's resistance to loads with consequent higher risk of fractures). We aimed to investigate the association between lumbar BSI and vertebral fractures (VFs) in acromegaly., Methods: Twenty-three patients with acromegaly (13 males, mean age 58 years; three with active disease) were evaluated for morphometric VFs, trabecular bone score (TBS), bone mineral density (BMD) and BSI at lumbar spine, the latter being corrected for the kyphosis as measured by low-dose X-ray imaging system (EOS®-2D/3D)., Results: Lumbar BSI was significantly higher in patients with VFs as compared to those without fractures (2.90 ± 1.46 vs. 1.78 ± 0.33, p = 0.041). BSI was inversely associated with TBS (rho -0.44; p = 0.034), without significant associations with BMD (p = 0.151), age (p = 0.500), BMI (p = 0.957), serum IGF-I (p = 0.889), duration of active disease (p = 0.434) and sex (p = 0.563)., Conclusions: Lumbar BSI corrected for kyphosis could be proposed as integrated parameter of spine arthropathy and osteopathy in acromegaly helping the clinicians in identifying patients with skeletal fragility possibly predisposed to VFs., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
89. Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies.
- Author
-
Birtolo MF, Pedersini R, Palermo A, Vena W, Morenghi E, Cristofolini G, Presciuttini B, Tabacco G, Naciu AM, Pigni S, Laganà M, Mazzoleni F, Cosentini D, Ciafardini A, Pagani M, Farina D, Balzarini L, Zambelli A, Torrisi R, Cianferotti L, Napoli N, Bossi AC, Lania AG, Berruti A, and Mazziotti G
- Subjects
- Humans, Female, Retrospective Studies, Adult, Middle Aged, Spinal Fractures prevention & control, Spinal Fractures etiology, Spinal Fractures epidemiology, Denosumab therapeutic use, Denosumab adverse effects, Osteoporosis drug therapy, Osteoporosis chemically induced, Breast Neoplasms drug therapy, Premenopause, Bone Density drug effects, Bone Density Conservation Agents therapeutic use, Diphosphonates therapeutic use
- Abstract
Background: Bone health management in premenopausal women with breast cancer (BC) under hormone-deprivation therapies (HDTs) is often challenging, and the effectiveness of bone-active drugs is still unknown., Methods: This retrospective multicenter study included 306 premenopausal women with early BC undergoing HDTs. Bone mineral density (BMD) and morphometric vertebral fractures (VFs) were assessed 12 months after HDT initiation and then after at least 24 months., Results: After initial assessment, bone-active drugs were prescribed in 77.5% of women (151 denosumab 60 mg/6 months, 86 bisphosphonates). After 47.0 ± 20.1 months, new VFs were found in 16 women (5.2%). Vertebral fracture risk was significantly associated with obesity (odds ratio [OR] 3.87, P = .028), family history of hip fractures or VFs (OR 3.21, P = .040], chemotherapy-induced menopause (OR 6.48, P < .001), preexisting VFs (OR 25.36, P < .001), baseline T-score less than or equal to -2.5 standard deviation (SD) at any skeletal site (OR 4.14, P = .036), and changes at lumbar and total hip BMD (OR 0.94, P = .038 and OR 0.88, P < .001, respectively). New VFs occurred more frequently in women untreated compared to those treated with bone-active drugs (14/69, 20.8% vs 2/237, 0.8%; P < .001) and the anti-fracture effectiveness remained significant after correction for BMI (OR 0.03; P < .001), family history of fractures (OR 0.03; P < .001), chemotherapy-induced menopause (OR 0.04; P < .001), and preexisting VFs (OR 0.01; P < .001)., Conclusions: Premenopausal women under HDTs are at high risk of VFs in relationship with high BMI, densitometric diagnosis of osteoporosis, preexisting VFs, and family history of osteoporotic fractures. Vertebral fractures in this setting might be effectively prevented by bisphosphonates or denosumab., Competing Interests: Conflict of interest: R.P. received consultancy fees from Roche, Novartis, Eli Lilly, Daiichi Sankyo, Gilead, Eisai, and Accord, outside the submitted work. A.P. reports lecture fees from Amgen, Theramex, and UCB, outside the submitted work. A.N. reports lecture fees from Theramex, outside the submitted work. G.T. reports lectures fees from Theramex and Abiogen, outside the submitted work. R.T. received research grants from Pfizer, consultancy fees from MSD, and lecture fees from Pfizer, Eli Lilly, Eisai, and Genomic Health outside the submitted work. A.Z. received consultancy fees from Roche, Novartis, Pfizer, Eli Lilly & Co., AstraZeneca, and Genomic Health outside the submitted work. L.C. received consultancy fees from UCB and lecture fees from Abiogen Pharma and Bruno Farmaceutici, outside the submitted work. A.C. Bossi reports research grants from Bayer SA, Lilly Italia SpA, MSD USA, and Novo Nordisk Italia SpA and personal fees from Sanofi Italia SpA, Boehringer Ingelheim Italia SpA, and AstraZeneca Italia SpA, outside the submitted work. A.L. received grants from Pfizer and lecture fees from Recordati, outside the submitted work. A.B. reports receiving grants and personal fees from Janssen Cilag, grants and personal fees from Astellas, and personal fees from Bayer outside the submitted work. G.M. received consultancy fees and preceptorship from Amgen–UCB and Sanofi and lectures fees from Theramex and Recordati. The other authors have nothing to declare., (© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
90. A new classification to characterize and predict treatment of acetabular bone defects.
- Author
-
Loppini M, Guazzoni E, Gambaro FM, La Camera F, Morenghi E, and Grappiolo G
- Subjects
- Humans, Female, Male, Aged, Middle Aged, Radiography, Aged, 80 and over, Reproducibility of Results, Adult, Retrospective Studies, Observer Variation, Acetabulum diagnostic imaging, Acetabulum surgery, Arthroplasty, Replacement, Hip methods, Reoperation statistics & numerical data
- Abstract
Background: The increasing amount of revision surgeries in total hip arthroplasty (THA) represents a burden for orthopedic surgeons given the complexity and unpredictability of this kind of surgery. The aim of the current study was to develop a new radiographic classification of acetabular bone defects stratify the severity of the lesion and to suggest the surgical strategy to address it., Methods: Radiographs of 151 consecutive patients who underwent acetabular revision surgery in our institution were collected to develop a new classification that groups the acetabular bone defects in three zones (A, B and C). The performance to predict treatment and inter- and intra-rater agreement were evaluated., Results: The ability of the newly proposed classification to predict treatment was 87.3% (k weighted: 0.65). The inter-rater reliability was 90.1% (k: 0.81), and the intra-rater reliability between the two sets of evaluations performed by the observer at 1-month distance was 97.5% (k: 0.94)., Conclusions: The newly proposed classification was able to characterize the extent of acetabular bone defects and predict pre-operatively the appropriate surgical treatment strategy in 87.3% of cases. It showed a strong agreement among raters and an almost perfect agreement among different measurements at 1 month distance. This new tool could be used in the preoperative assessment to drive the use of secondary level image examinations and the type of surgical management., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
91. Predicting the pregnancy outcome: Uncovering the link between β-hCG, patient factors and live birth in IVF.
- Author
-
Cirillo F, Secchi M, Busnelli A, Morenghi E, Di Segni N, Baggiani A, and Levi-Setti PE
- Subjects
- Humans, Female, Pregnancy, Adult, Retrospective Studies, Embryo Transfer statistics & numerical data, Young Adult, Predictive Value of Tests, Male, Middle Aged, Chorionic Gonadotropin, beta Subunit, Human blood, Live Birth epidemiology, Fertilization in Vitro, Pregnancy Outcome
- Abstract
Objective: The objectives of the study were to correlate live birth rate with the initial level of β-hCG in all patients undergoing embryo transfer and develop a predictive model of live birth based on patients' and assisted reproductive technology (ART) characteristics., Study Design: Single-center retrospective cohort study, including a total of 7587 positive first serum β-hCG from women who performed fresh and frozen embryo transfer. Twenty-one variables related to patient characteristics and treatment modalities were analyzed by step-wise univariate analysis followed by multivariate analysis. The study included women between 18 and 45 years with a positive (>20 IU/L) serum β-hCG between January 2011 and December 2020 while it excluded cycles from donation of gametes, PGT and >3 embryos transferred simultaneously., Main Results and the Role of Chance: Among the positive serum β-hCG measurements 5085 (67.0 %) resulted in live births. β-hCG was higher in the live birth group (691 IU/L) compared to the failed pregnancies group (304 IU/L) (p500 IU/mL provided a positive predictive value for live birth of 85.3 % (95 %CI 84.0-86.4). Failed pregnancies were more common among older maternal and paternal age. Previous abortions were more common in the failed pregnancies group (25.0 %) compared to the live birth group (19.4 %). The most common indication to treatment was male infertility, accounting for a larger portion in the live birth group (41.7 %). At multivariate analysis, the factors independently associated with live birth were: first serum β-hCG (OR 1.35, 95 %CI 1.32-1.37), maternal age (OR 0.93, 95 %CI 0.91-0.95), previous abortions (OR 0.77, 95 % CI 0.68-0.88). The number of embryos transferred showed a positive correlation below a maternal age of 39 (<35 years old OR 1.60, CI 95 % 1.32-1.94; <39 years old OR 1.27 CI 95 % 1.09-1.47). The prediction model incorporating these four variables resulted in a sensitivity and specificity with an area under the ROC curve of 0.798., Conclusion: The study confirms the importance of the first value of β-hCG and proposes a predictive model that takes into account maternal age, number of embryos transferred, and obstetric history, thereby aiding in couples' counseling and ultimately improve patients' care., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
92. Impact of Preoperative Malnutrition on Patients with Pancreatic Neoplasms Post-Duodenopancreatectomy: A Retrospective Cohort Study.
- Author
-
Pellegrinelli A, Mancin S, Brolese A, Marcucci S, Roat O, Morenghi E, Morales Palomares S, Cattani D, Lopane D, Dacomi A, Coldani C, Tomaiuolo G, Dal Bello S, Capretti G, and Mazzoleni B
- Subjects
- Humans, Retrospective Studies, Male, Female, Middle Aged, Aged, Risk Factors, Length of Stay statistics & numerical data, Body Mass Index, Preoperative Period, Nutritional Status, Adult, Patient Discharge statistics & numerical data, Cohort Studies, Malnutrition etiology, Malnutrition diagnosis, Pancreatic Neoplasms surgery, Pancreatic Neoplasms complications, Pancreaticoduodenectomy adverse effects, Postoperative Complications etiology, Postoperative Complications epidemiology, Nutrition Assessment
- Abstract
Background: Preoperative malnutrition is a significant factor in patients with pancreatic tumors undergoing pancreaticoduodenectomy. The aim of this study was to assess the association between preoperative malnutrition and delayed discharge within a ten-day timeframe and potential correlations between preoperative malnutrition and postoperative surgical complications., Methods: A retrospective cohort study was conducted, recruiting a final sample of 79 patients with benign or malignant cephalic pancreatic tumors from 2015 to 2022. The risk of malnutrition was assessed using the Malnutrition Universal Screening Tool, while length of hospital stay and relevant clinical data were extracted from clinical documentation., Results: The preoperative malnutrition risk was high in 21.52% of the sample, moderate in 36.71%, and low in 41.77%. Body mass index (BMI) ( p = 0.007) and postoperative surgical complications ( p < 0.001) were significantly correlated with delayed discharge. No statistically significant differences were found between levels of malnutrition risk and delayed discharge ( p = 0.122), or postoperative surgical complications ( p = 0.874)., Conclusions: Postoperative complications and BMI emerge as significant risk factors. The limited sample size may have compromised the collection of homogeneous and significant data. Future studies should evaluate the implementation of personalized nutritional screening tools, nutritional assessment plans, and the involvement of specialized health professionals.
- Published
- 2024
- Full Text
- View/download PDF
93. Real-world sex differences in type 2 diabetes patients treated with GLP-1 receptor agonists.
- Author
-
Piccini S, Favacchio G, Morenghi E, Mazziotti G, A Lania AG, and Mirani M
- Subjects
- Humans, Male, Female, Retrospective Studies, Middle Aged, Aged, Sex Factors, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2 drug therapy, Glucagon-Like Peptide-1 Receptor agonists, Hypoglycemic Agents therapeutic use, Cardiovascular Diseases epidemiology, Cardiovascular Diseases prevention & control
- Abstract
Aims: To evaluate the determinants of cardiovascular (CV) protection in men and women treated with glucagon-like peptide-1 receptor agonists (GLP1-RA)., Methods: Retrospective cohort study of 550 patients (43% women), with and without established CV disease, followed at a single center after the first prescription of a GLP1-RA. We analyzed the determinants of major adverse cardiovascular events (MACE) in men and women., Results: The rate of MACE was similar between sexes. In primary prevention, among men, older age (HR 1.13, 95 % C.I. 1.05-1.22; P = 0.001) and GLP-1 RA withdrawal by time (HR 2.77, 95 % C.I. 1.15-6.68; P = 0.023) increased the HR for MACE. Among women, significant predictors of MACE were diabetes duration (HR 1.05, C.I. 1.01-1.10; P = 0.020), GLP-1 withdrawal by time (HR 2.84, 95 % C.I. 1.13-7.10; P = 0.026) and BMI at GLP-1 RA withdrawal (HR 1.08, 95 % C.I. 1.01-1.15; P = 0.026). For individuals with prior CV disease, the HR for MACE was solely impacted by GLP-1 withdrawal over time in males (HR 2.18, 95 % C.I. 1.10-4.30; P = 0.025) and by older age at GLP-1 RA initiation (HR 1.17, 95 % C.I. 1.03-1.33; P = 0.015) in females., Conclusions: Although MACE rates were similar, the factors contributing to MACE differed by sex., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
94. A methodological framework for rigorous systematic reviews: Tailoring comprehensive analyses to clinicians and healthcare professionals.
- Author
-
Mancin S, Sguanci M, Anastasi G, Godino L, Lo Cascio A, Morenghi E, Piredda M, and Grazia De Marinis M
- Subjects
- Humans, Reproducibility of Results, Systematic Reviews as Topic methods, Health Personnel, Research Design
- Abstract
Systematic reviews represent a fundamental study design, providing the highest level of evidence across diverse research inquiries, encompassing both public health and clinical research and practice. However, for healthcare professionals, the process of selecting, synthesizing, and interpreting evidence can be challenging, and requires specialized skills. Therefore, it is imperative to explore innovative solutions aimed at simplifying and making the traditional systematic review process more accessible while ensuring the validity and reliability of results. In this perspective, our research objective is to develop a systematic review framework that, while maintaining a rigorous methodological approach, streamlines the process for healthcare professionals. This study describes such approach in every phase, from the collection of evidence to the writing of the text, creating a guide for the healthcare professional who approaches this type of research. The qualitative and organizational analysis tools are also described, providing useful information for the use of non-paid programs. This systematic review aims to develop a framework with a rigorous methodological approach that allows simplify the process for clinicians and healthcare professionals. The implementation of this methodology in clinical practice offers new perspectives to ensure a thoughtful consideration and application of scientific evidence and opens the way to innovative and easily accessible solutions to facilitate the conduct of systematic reviews in the clinical care setting., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
95. Clinical and Radiographic Outcomes of Hip Revision Surgery and Cerclage Wires Fixation for Vancouver B2 and B3 Fractures: A Retrospective Cohort Study.
- Author
-
Di Matteo V, La Camera F, Carfì C, Morenghi E, Grappiolo G, and Loppini M
- Abstract
Background: The number of patients presenting with periprosthetic hip fractures has increased in recent decades., Methods: Patients who underwent hip revision arthroplasty procedures for Vancouver type B2 and B3 fractures between 2010 and 2021 were included. The primary intended outcome of this study was to determine the reintervention-free survival rate. The secondary intended outcome was to determine clinical and radiographic assessment outcomes at the time of follow-up, and the correlation between time to surgery and postoperative Harris hip score (HHS)., Results: A total of 49 patients with mean age of 71.2 ± 2.3 (37-88) years old were included. Overall, the Kaplan-Meier method estimated a survival rate of 95.8% (CI 84.2% to 98.9%) at one year, 91.1% (CI 77.9% to 96.6%) at two years, and 88.5% (CI 74.4% to 95.1%) at three, and up to 10, years. The mean limb length discrepancy (LLD) improved from -13.3 ± 10.5 (range -39 to +10) mm at the preoperative stage to -1.16 ± 6.7 (range -17 to +15) mm, p < 0.001 postoperative. The mean HHS improved from 31.1 ± 7.7 (range 10 to 43) preoperative to 85.5 ± 14.8 (range 60 to 100), p < 0.001 postoperative. Postoperative HHS was not affected by preoperative time to surgery., Conclusions: Revision arthroplasty is an effective treatment for Vancouver type B2 and B3 fractures.
- Published
- 2024
- Full Text
- View/download PDF
96. Dysphagia screening post-stroke: systematic review.
- Author
-
Mancin S, Sguanci M, Reggiani F, Morenghi E, Piredda M, and De Marinis MG
- Subjects
- Humans, Cross-Sectional Studies, Mass Screening, Nutritional Status, Deglutition Disorders diagnosis, Deglutition Disorders etiology
- Abstract
Background/scope: Stroke is one of the main causes of death, especially when associated with dysphagia. Hence, the assessment of nutritional status and aspiration risk is important to improve clinical outcomes. The aim of this systematic review is to identify which are the most suitable dysphagia screening tools in chronic post-stroke patients., Methodology: A systematic literature search was conducted for articles published from 1 January 2000 to 30 November 2022 in the Cochrane Library, PubMed, Embase, CINAHL, Scopus and Web of Science databases, including primary studies providing quantitative or qualitative data. Additionally, a manual search was conducted scanning the reference lists of relevant articles and Google Scholar was searched to retrieve additional records. The process of screening, selection and inclusion of the articles, as well as the assessment of risk of bias and methodological quality, were conducted by two reviewers., Results: Out of the 3672 records identified, we included 10 studies, mostly (n=9) cross-sectional, evaluating screening for dysphagia in 1653 chronic post-stroke patients. Volume-Viscosity Swallow Test was the only test applied in multiple studies with adequate sample size, demonstrating high diagnostic accuracy (sensitivity=96.6%-88.2%; specificity=83.3%-71.4%) compared with the videofluoroscopic swallowing study., Conclusions: Dysphagia is an important complication in chronic post-stroke patients. Early identification of this condition through screening tools with adequate diagnostic accuracy is of paramount importance. The limited number of studies available and their small sample sizes may be a limitation to this study., Prospero Registration Number: CRD42022372303., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
97. Clinical and radiological outcomes of an uncemented metaphyseal short stem at minimum 10 years of follow-up: a prospective observational study.
- Author
-
Grappiolo G, Gambaro FM, Spera M, Chiappetta K, Morenghi E, and Loppini M
- Subjects
- Humans, Treatment Outcome, Prosthesis Design, Radiography, Follow-Up Studies, Reoperation, Hip Prosthesis, Arthroplasty, Replacement, Hip methods
- Abstract
Purpose: There is growing interest around short stems as they provide a less invasive approach for total hip arthroplasty preserving bone stock for a possible revision surgery if required. The main purpose of this work was to assess the long-term performance of an uncemented metaphyseal short stem in terms of survival rate and in addition its clinical and radiological outcomes., Materials and Methods: From January to December 2010, we prospectively enrolled all consecutive patients undergoing primary total hip arthroplasty with an uncemented metaphyseal short stem in our institution with a minimum follow-up of 10 years. The radiographic features investigated were the varus-valgus stem orientation, areas of osteolysis and radiolucencies, stress shielding, and heterotopic calcifications. The clinical outcomes were measured using the HHS., Results: A total of 163 patients (172 hips) were finally included and the measured survival rate at 10 years was 99.6%. The average HHS increased from 55.0 preoperatively to 97.8 at the last follow-up (p < 0.0001). Among them, 137 patients (164 hips) were also available for radiographic assessment. Mild varus malalignment was observed in 40% of cases and remained stable in the serial X-rays and was not associated with step loosening. Mild stress shielding was observed around 13 stems (9%) and moderate only around 3 implants., Conclusion: In conclusion, the uncemented metaphyseal short stems showed excellent survival and clinical results at 10 years and at a radiographical level very low stress shielding was observed; moreover, besides the high frequency of varus alignment the implanted stems was not associated with revision surgery or with worse clinical outcomes., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
98. A randomized prospective comparative study on sinonasal morbidity and quality of life of transsphenoidal endoscopic surgery for pituitary adenomas: endonasal versus trans-septal approach.
- Author
-
Ferreli F, Lasagna C, Canali L, Baram A, Bono BC, Tropeano MP, Pirola F, Morenghi E, Mercante G, Spriano G, Milani D, Lasio G, and Colombo G
- Subjects
- Humans, Quality of Life, Prospective Studies, Treatment Outcome, Nose surgery, Endoscopy, Pituitary Neoplasms surgery
- Abstract
Purpose: Endoscopic endonasal transsphenoidal approach (Endonasal approach) is commonly used to treat pituitary adenomas. The extent of dissection possibly changes the anatomy and the physiology of the nasal cavities and could give rise to post-operative morbidity and the quality of life (QoL). The purpose of this study was to investigate sinonasal morbidity and general QoL in patients who underwent surgery for treatment of pituitary adenoma, comparing Endonasal and endoscopic trans-septal transsphenoidal approach (Trans-septal approach)., Methods: A prospective observational study, recruiting 40 patients undergoing surgery for pituitary adenoma, 20 via Endonasal approach and 20 via Trans-septal approach at our institution. Surveys with Sinonasal Outcome Test-22 (SNOT-22), Chronic Sinusitis Survey (CSS), and Short Form Health Survey 36 version 2 (SF-36v2) were obtained to collect QoL data pre- and postoperatively., Results: All the 40 patients completed the questionnaires. At 6 months postoperatively, the SNOT-22 and CSS score shows significant improvements both in Endonasal approach (p = 0.01) and in Trans-septal approach (p = 0.02). No significant difference in sinonasal morbidity is observed between the two groups for SNOT-22 (p = 0.13) and CSS scores, except for sinus headache (p = 0.49), with a better score in Endonasal approach. The mean SF-36v2 scores remain the same in pre- and post-operative periods, but an improvement in time is seen in general health (p = 0.027), and general health compared to one year ago (p < 0.001)., Conclusions: Endoscopic transsphenoidal surgery has negligible morbidity and does not negatively affect the nasal function in the long term. Endonasal approach and Trans-septal approach are comparable in terms of morbidity outcomes and general QoL, leaving the choice of the approach to the surgeon preference., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
99. Ten-Year Follow-Up of Orbital Volume Augmentation With Calcium Hydroxyapatite Filler in Postenucleation Socket Syndrome.
- Author
-
Di Maria A, Ferraro V, Trenti N, Morenghi E, Gaeta A, Vinciguerra P, and Confalonieri F
- Subjects
- Humans, Follow-Up Studies, Retrospective Studies, Orbit surgery, Syndrome, Durapatite, Enophthalmos diagnosis, Enophthalmos etiology, Enophthalmos surgery
- Abstract
Purpose: To describe the efficacy and persistence of injectable calcium hydroxyapatite (CAHY) to correct orbital volume deficit in postenucleation socket syndrome., Methods: An observational study was conducted as a clinical review of all patients in the authors' practice who received injectable CAHY placed in the extraconal and intraconal space to increase orbital volume with a 10-year follow up. The amount of CAHY to be injected was defined according to the degree of orbital volume deficit. Patients previously treated with radiotherapy or with a conjunctival fornix insufficient to accommodate the external prosthesis were excluded. All the patients with at least 10 years of follow up were included in the study., Results: Thirty-one postenucleation socket syndrome patients received injectable CAHY for orbital volume augmentation, with a 10-year follow up. The mean amount of preoperative relative enophthalmos measured by Hertel's exophthalmometry was 14.16 ± 2.15. An increase in the mean orbital volume of 3.35 ± 0.91 at 6 months and 2.97 ± 1.35 at 10 years was obtained. The mean follow-up was 219 ± 18 months (range, 184-240). Patients demonstrated clinical and cosmetic improvement that was observed to continue for 10 years. The complications were peribulbar ecchymosis, 2 extrusions of the internal prosthesis, and 2 ptosis., Conclusions: Injectable CAHY provides safe, simple, repeatable, and cost-effective technique to treat volume deficiency in the enophthalmic orbit in the long term. The volume augmentation obtained with this semipermanent filler demonstrated a lasting effect in the orbit with negligible loss of volume at 10 years., Competing Interests: The authors have no financial or conflicts of interest to disclose., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
100. Incidence of Tracheal Stenosis in ICU Hospitalized COVID-19 Patients: Results from a Prospective, Observational, Multicenter Study.
- Author
-
Perroni G, Radovanovic D, Mondoni M, Mangiameli G, Giudici VM, Crepaldi A, Giatti V, Morenghi E, Stella GM, Pavesi S, Mantero M, Corsico AG, Spotti M, Premuda C, Mangili SA, Franceschi E, Narvena VM, Vanoni N, Pilocane T, Russo G, Di Marco F, Alloisio M, Aliberti S, Marulli G, Bertuzzi AF, Cipolla G, Centanni S, Blasi F, Santus P, and Cariboni U
- Abstract
Background: Tracheal stenosis represents a fearsome complication that substantially impairs quality of life. The recent SARS-CoV-2 pandemic increased the number of patients requiring invasive ventilation through prolonged intubation or tracheostomy, increasing the risk of tracheal stenosis. Study design and methods: In this prospective, observational, multicenter study performed in Lombardy (Italy), we have exanimated 281 patients who underwent prolonged intubation (more than 7 days) or tracheostomy for severe COVID-19. Patients underwent CT scan and spirometry 2 months after hospital discharge and a subsequent clinical follow-up after an additional 6 months (overall 8 months of follow-up duration) to detect any tracheal lumen reduction above 1%. The last follow-up evaluation was completed on 31 August 2022. Results: In the study period, 24 patients (8.5%, CI 5.6-12.4) developed tracheal stenosis in a median time of 112 days and within a period of 200 days from intubation. Compared to patients without tracheal stenosis, tracheostomy was performed more frequently in patients that developed stenosis (75% vs 54%, p = 0.034). Tracheostomy and alcohol consumption (1 unit of alcohol per day) increased risk of developing tracheal stenosis of 2.6-fold ( p = 0.047; IC 0.99-6.8) and 5.4-fold ( p = 0.002; CI 1.9-16), respectively. Conclusions : In a large cohort of patients, the incidence of tracheal stenosis increased during pandemic, probably related to the increased use of prolonged intubation. Patients with histories of prolonged intubation should be monitored for at least 200 days from invasive ventilation in order to detect tracheal stenosis at early stage. Alcohol use and tracheostomy are risk factors for developing tracheal stenosis.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.